45

1391 (60 ) 4 -

90/11

/16 :

91

/5/5 :

: . . . ( ) ( ) . . 75 65 25 . ¬ . . ÌÙ ÔÜÔ ÌÝ . . ØÜÔ

.

. :

* : :

:

1391 (60 ) 4 -

*Email: ah.haghighi292@yahoo.com

46

1391 (60 ) 4 -

1. High density lipoprotein2. Tumor necrosis factor 3. Interleukin 6

. ( ) ( ) -

.(32) (21)

. 1(ØÜÔ-Ý) . 3(×Ô-6) 6 2( ) . .(2 24) - . . .(30)

2005 . . 55-52 . .(22) . .(16) ×Ô-6 2 .(20 9)

.(6) 2 .(3)

47

1391 (60 ) 4 -

(33) . . .(17) .

.(22 39) .

. (31) . (14)

.

(27) . (2011 ) .

. (26) . (5) . (2011) . 2 (23)

. (29) 70 . ØÜÔ ÔÜÔ

48

1391 (60 ) 4 -

. .

.

. 45 �30 . . (19) (25 ) . .

. - . 1(ÉØÎ) . ( ) ( )

.

. 75 -65 . . 25 . .

1. Waist to hip ratio

49

1391 (60 ) 4 -

. 8-6 1389

.

( ) . .

. 10-8 5 . 4000 . . -24

. 48

. 0/16 (Ðײ¬®¿= 6/5)

. 1 (Ðײ¬®¿= 6/5) . 5 (Ðײ¬®¿= 6/5) . (ÔÜÔ-Ý) 1 ØÜÔ-Ý . 3 . (ÌÝ) 3 (ÌÙ) . 1 .

ØÑÓß- ×Î [ (³¹/¼´) × (³Ë/Ô) ] 405

50

1391 (60 ) 4 -

.(15) . 24 ( ) .

. . . (ʱ2³¿¨

) ( 1/6 / 1) .(28)

 

Ðä0/05 *

.1

Ð

( )93/8o14/493/2o14/5-0/6o3/90/042

91/3o11/4* 89/4o10/7-1/9o3/5 )

(

31/4o3/731/4o3/90/006o1/10/004

30/6o4/2* 29o4/4-1/627o1/04

( )

0/98o0/050/98o0/050/001o0/010/019

0/97o0/04*0/95o0/05-0/024o0/02

35/5o5/136/0o4/80/45o1/40/00137/1o2/6* 29/7o3/3-7/41o2/3

) (

39/3o3/839/3o4/30/004o2/10/012

38/7o5/6* 41/2o5/22/5o1/8

51

1391 (60 ) 4 -

.2

Ð

) (

4/78o3/54/8o3/30/11o0/70/005

4/5o2/9*1/1o0/6-3/37o3/1

)

(

6/5o2/84/8o2/1-1/74o1/20/491

4/5o2/23/7o1/1-0/84o2/4

)(

79/9o6/174/5o8/1-5/4o11/90/023

87/6o8/1* 71/2o2/1-16/4o7/2

1/3o0/590/89o0/45-0/40o0/750/853

1/0o0/540/66o0/20-0/34o0/56

)

(

130o46/3123o28/6-6/5o39/00/889

130o41/6126o33/5-3/6o51/6

)

(

153o15/9 163o21/10/3o25/30/947

169o18/9179o28/19/7o11/9

)(

31/2o5/228/5o4/0-2/7o2/90/040

30/1o3/530/4o3/00/36o3/3

)

(

96o19/4110o19/514/3o25/50/670

113o17/3123o25/310/0o17/8

 

Ðä0/05 *

52

1391 (60 ) 4 -

.3

Ð

( )1400o1541509o200109o1750/289

1481o2221498o22316o162

( )

12/6o2/312/7o1/10/12o2/50/43

15/1o2/613/5o2-2/4o2/2

( )

56/8o557/6o3/60/75o5/10/27

57/3o6/355/2o4/8-2/1o8/7

( )

30/3o4/929/3o3/7-1/1o6/60/35

27/3o5/230/2o4/82/9o8/8

5020ÍßÛØßÒ-ÍØ

.(38)

- ¬ . . Ðä0/05

. 16 ÍÐÍÍ

- ¬ . 2 1 ¬ . 1 ʱ2³¿¨

53

1391 (60 ) 4 -

.(1 ) ¬ 2 ØÜÔ . ÔÜÔ ÌÙ ÌÝ

.(2 ) 3

.(3 )

ÔÜÔ ÌÙ . ÌÝ ØÜÔ . (2009) (2007) (2010) . (2010) 85-65 12-8

. 5-4

.(14) (25) 70 60 ÔÜÔ ØÜÔ ÞÓ× .

. (12) 75 . 2 ØÜÔ ÔÜÔ ÞÓ× .

. (25) .

54

1391 (60 ) 4 -

.

. (27) 400 300

. (29) 70 75-50 . . 2) ( .

. . (11) . 10-5

.(1 4)

20 . .

. (29) . . -80 8-2 . .

. .

55

1391 (60 ) 4 -

. (37) 3Ì3Ô1 . ( ) . ) ( ) ( . 3Ì3Ô1

. (22) . ) . (36) (

ÞÓ× .(10 37) . ÞÓ×

. (25) . . 1 (8) ØÜÔ ÌÙ

-3- ) Õ×Ð3ÙÝ ( ÚÙ×-1/ (34)

. . .

. (35) . ØÜÔ

56

1391 (60 ) 4 -

. ÌÙ (18) ÔÜÔ

. (13) ÔÜÔ-Ý . . ØÜÔ-Ý . ÔÜÔ-Ý . ÔÜÔ ÌÙ ÌÝ ØÜÔ . .

. . . .(14) .(22)

.(7)

(31) . (14) . . ÉØÎ

ÞÓ×

. (10) . . .

. ×Ô-6

.

57

1391 (60 ) 4 -

1384 .1.49-41 32

1385 .2

.29-19 34 . .3 « (1388)

.157-151 2 11 1389 .4

.46-33 3 18 8 1389 .5 3 15

.242-2336. Antuna, B.; Feve, B.; Fellahi, S.; Bastard J. (2008). "Adipokines: the missing link between insulin resistance

and obesity". Diabetes Metab, 34: 2-11.7. Arner, P. (2006). "Visfatin�a true or false trail to type 2 diabetes mellitus", Journal of Clinical Endocrinology

and Metabolism, 91: 28�30.8. Arya, R.; Blangero, J.; Williams, K.; Almasy, L.; Dyer, TD.; Leach, RJ.; et al. (2002). "Factors of insulin

resistance syndrome related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican Americans", Diabetes, 51: 841-7.

9. Beqtowski, J. (2006). "Apelin and visfatin: Unique benecial adipokines upregulated in obesity?" Med Sci Monit, 12: 112-9.

10. Berndt, J.; Kloting, N.; Kralisch, S.; Kovacs, P.; Fasshauer, M.; Schon, MR.; et al. (2005). "Plasma visfatin concentrations and fat depot-specic mRNA expression in humans", Diabetes, 54: 2911�6.

11. Berndt, J.; Kloting, N.; Kralisch, S.; Kovacs, P.; Fasshauer, M.; Schon, MR.; et al. (2005). "Plasma visfatin concentrations and fat depot specic mRNA expression in humans", Diabetes, 54: 2911-2916.

12. Brema, I.; Hatunic, M.; Finucane, F.; Burns, N.; Nolan, JJ.; Haider, D.; et al. (2008). "Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus", Diabetes Obes Metab, 10: 600-602.

13. Chen, C.; Li, T.; Li, C.; Liu, C.; Lin, W.; Wu M. (2007). "The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women", 52: 1216-1220.

14. Choi, K.; Kim, J.; Cho, G.; Baik, S.; Park, H.; Kim, S. (2007). "Effect of exercise training on plasma visfatin and eotaxin levels", European Journal of Endocrinology, 157: 437-442.

15. Cummings DM, Henes S, Kolasa KM, Olsson J, Collier D. (2008). �Insulin resistance status: Predicting weight

58

1391 (60 ) 4 -

response in overweight children�. Arch Pediatr Adolesc Med. 162:764-768.16. Dahl, T.; Yndestad, A.; Skjelland, M.; Oie, E.; Dahl, A.; Michelsen, A.; et al. (2007). "Increased expression

of visfatin in macrophages of human unstable carotid and coronary atherosclerosis", Possible role in inammation and plaque destabilization Circulation, 115: 972-980.

17. Davutoglua, M.; Ozkayab, M.; Gulera, E.; Garipardca, M.; Gursoya, H.; Karabibera, H.; et al. (2009). "Plasma visfatin concentrations in childhood obesity: relationships to insulin resistance and anthropometric indices", Swiss Med Wkly, 139: 22-7.

18. De, L.; Aller, R.; Conde, R.; Izaola, O. (2009). "Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle", Nutrition, 21: 805-809.

19. Flegal, KM.; Carroll, MD.; Ogden, CL.; Curtin, LR. (2010). "Prevalence and trends in obesity among US adults, 1999-2008", JAMA, 303: 235-241.

20. Fonseca, M.; Takada, J.; Alonso, M.; Lima, F. (2007). "Adipose tissue as an endocrine organ: from theory to practice", J Pediatr, 83: 192-203.

21. Ford, ES.; Mokdad, AH.; Giles, WH.; Brown, DW. (2003). "The metabolic syndrome and antioxidant concentrations", Diabetes, 52: 2346-2352.

22. Fukuhara, A.; Matsuda, M.; Nishizawa, M.; Segawa, K.; Tanaka, M.; Kishimoto, K.; et al. (2005). "Visfatin: a protein secreted by visceral fat that mimics the effects of insulin", Science, 21: 366-376.

23. Ghanbari-Niaki, A.; Saghebjoo, M.; Soltani, R.; Kirwan, J. (2010). "Plasma visfatin is increased after high-intensity exercise", Ann Nutr Metab, 57:3�8.

24. Greenberg, AS.; McDaniel, ML. (2002). "Identifying the links between obesity, insulin resistance and beta cell function: potential role of adipocyte derived cytokines in the pathogenesis of type 2 diabetes", Eur J Clin Invest, 32: 24-34.

25. Haider, DG.; Pleiner, J.; Francesconi, M.; Wiesinger, GF.; Muller, M.; Wolzt, M. (2006). "Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes", J Clin Endocrinol Metab, 91: 4702-4704.

26. Haus, J.; Solomon, T.; Marchetti, C; Oleary, V.; Brooks, L.; Gonzalez, F.; et al. (2009). "Decreased visfatin after exercise training correlates with improved glucose tolerance", Medicine & Science in Sports & Exercise, 41: 1255-1260.

27. Lee, KJ.; Shin, YA.; Lee, KY.; Jun, TW.; Song, W. (2010). "Aerobic exercise training-induced decrease in plasma visfatin and insulin resistance in obese female adolescents", Int J Sport Nutr Exerc Metab, 20: 275-81.

28. Mackenzie, B. (2005). "101 Performance evaluation tests", 33 -34.29. McKenzie, JA. (2010). "The inuence of visfatin and visfatin gene polymorphisms on glucose and obesity-

related variables and their responses to aerobic exercise training", Kinesiology, 303: 314-328.30. Nicklas, BJ.; Berman DM. (2002). "Endurance exercise and adipose tissue" CRC Press LLC, 54: 79-88.31. Pagano, C.; Pilon, C.; Olivieri, M.; Mason, P.; Fabris, R.; Serra, R.; et al. (2006). "Reduced plasma visfatin/

pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans", Journal of Clinical Endocrinology and Metabolism 91: 3165�3170.

32. Sattar, N.; Gaw, A.; Scherbakova, O.; Ford, I.; Reilly, DS.; Haffner, SM.; et al.(2003). "Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of

59

1391 (60 ) 4 -

Scotland Coronary Prevention Study", Circulation, 108: 414�419. 33. Sun, G.; Bishop, J.; Khalili, S.; Vasdev, S.; Gill, V.; Pace, D.; et al. (2007). "Serum visfatin concentrations are

positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men", Am J Clin Nutr, 85: 399-404.

34. Vanhaesebroeck, B.; Ali, K.; Bilancio, A.; Geering, B.; Foukas, LC. (2005). " Signalling by PI3K isoforms: insights from gene targeted mice", Trends Biochem Sci, 30: 194- 204.

35. Wang, T.; Zhang, X.; Bheda, P.; Revollo, JR.; Imai, S.; Wolberger, C. (2006). "Structure of Nampt/ PBEF/ Visfatin, a mammalian NAD + Biosynthetic enzyme", Nat Struct, 13: 661-662.

36. Wannamethee, SG.; Shaper, AG.; Morris, RW.; Whincup, PH. (2005). "Measures of adiposity in the identication of metabolic abnormalities in elderly men", Am J Clin Nutr, 81: 1313�1321.

37. Wen, Y.; Wang, HW.; Wu, J.; Lu, HL.; Hu, XF.; Cianone K. (2010). "Effects of fatty acid regulation on visfatin gene expression in adipocytes", Chin Med J (Engl), 119: 1701-1708.

38. Williams, M H. (2010). Nutrition for health, tness and sport, MC craw Hill Sixth Edition, 466-467.39. Zhong, M.; Tan, HW.; Gong, HP.; Wang, SF.; Zhang, Y.; Zhang, W. (2008). "Increased serum visfatin in

patients with metabolic syndrome and carotid atherosclerosis", Clin Endocrinol(Oxf), 69: 878-884.

.